As of the last check, Acutus Medical Inc. (AFIB) shares were up 1.53% to $15.28 in premarket trading. Acutus stock fell -2.78 percent to close last session at $15.05. During the past 50 days, AFIB stock has traded 0.56 million shares, a volume which is higher than its trading volume of 0.22 million shares traded on the day. Currently, AFIB has a market capitalization of $415.98 million and 28.03 million outstanding shares. After its common shares offering, AFIB stock is gaining ground.

What has AFIB offering?

Acutus is a company that defines and treats cardiac arrhythmias so they can be diagnosed and treated more effectively. AFIB is committed to making electrophysiology a more efficient and effective field of treatment for more patients with the help of a unique array of products and technologies.

By developing its own products, making acquisitions, and partnering with global companies, AFIB has established itself as a global player. With its broad range of highly differentiated electrophysiology products, AFIB offers its customers a complete solution to combat cardiac arrhythmias by catheter.

Acutus announced that it is offering 5,500,000 shares of its common stock at a price of $14 per share in an underwritten public offering.

• AFIB is offering all of the shares of its common stock.
• AFIF expects the gross proceeds from the offering to be $77.0 million, before taking into account underwriting discounts and commissions and other offering expenses.
• As long as the closing conditions are satisfied, AFIB anticipates closing the offering on July 19, 2021.
• Underwriters can also buy up to an additional 825,000 AFIB shares for a price to the public by AFIB, less underwriting discounts and commissions, for a period of 30 days from the date of the public offering.
• AFIB’s offering is solely managed by The Goldman Sachs.

Also this week, Accutus announced preliminary non-audited results for the second quarter of 2021.

Key Highlights:

• Compared to $3.6 million in Q1 2021 and $1.1 million in Q2 2020, preliminary quarter-to-quarter net sales in Q2 2021 are expected to be roughly between $4.6 and $4.7 million.
• According to AFIB, there will be 68 second-generation AcQMap consoles installed worldwide by June 30, 2021, compared to 57 as of March 31, 2021.
• In June 2021, 70 of AFIB’s AcQMap consoles were installed, bringing the total installed base to 75.
• AFIB’s direct businesses experienced over 40% sequential growth over the first quarter of 2021, a trend it was pleased with during the second quarter.

An overview of AFIB’s other efforts:

Acutus Medical (AFIB) has received US Investigational Device Exemption in order to institute clinical trials of the AcQBlate Force-Sensing Ablation Catheter and System in paroxysmal and persistent atrial fibrillation. Likewise, AFIB will be in person at Heart Rhythm Society’s annual meeting in Boston, from July 28 to July 31, for a symposium devoted to Rhythm Theater, which will be held in conjunction with the company’s first meeting.